The center for research on genomics and global health (CRGGH) aims to study the effect of point mutations in a gene of interest on insulin secretion/dysregulation and CRGGH anticipates that this…

Ended Purchase Order Awarded Last action

Contract number
HHSN268201700116A
Awardee
Awarding agency
Obligated
$19,950

Award facts

Opportunity
Contract value 46% obligated
  • $19,950.00 Current, with exercised options
  • $43,450.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Great Britain, United Kingdom

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00003 -$23,500
Other Administrative Action P00002 -$19,950
Exercise an Option 1 $23,500
Original award $39,900

Description

The center for research on genomics and global health (CRGGH) aims to study the effect of point mutations in a gene of interest on insulin secretion/dysregulation and CRGGH anticipates that this data will be useful to derive new biological insights regarding the role of the gene of interest in T2D.

Quick answers

Who was awarded contract HHSN268201700116A?

HHSN268201700116A was awarded to Revvity Discovery LIMITED by National Heart Lung and Blood Institute (National Institutes of Health) on February 22, 2017.

How much is contract HHSN268201700116A worth?

The government has obligated $19,950 on HHSN268201700116A. Its potential value, with all options, is $43,450.

Was contract HHSN268201700116A competed?

The extent of competition for HHSN268201700116A was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award